XOMA may still be grappling with the numerical value of the CRP cutoff.
Agree that that is a possibility - but IMO I suspect that they realize that their bigger concern is the vast number of potential competitors once they find an indication and publish details. There are at least 2 IL-1 blockers and in many cases the TNF blockers work for the same indication.
Market Data 
Markets 
AI
